Publications found:
73,128
Sort by:
Mirabegron Gets JP Approval – Expecting US Filing & Approval In Time!
US$ 90.00
... rating on Astellas following announcement of JP approval for Betanis / mirabegron (β3-AR agonist, overactive bladder syndrome (OAB). Mirabegron is a key strategic product for ... able to maintain its leadership in the growing OAB market. Mirabegron will be targeted for those patients who are intolerant to ...
June 2011
4 pages
NOVARTIS, NVA237 ready to enter LAMA market: Spiriva domination under threat!!
US$ 90.00
... daily LAMA), meeting both, primary and the secondary endpoints. NVA237 demonstrated comparable safety and efficacy data vs. PFE’s Spiriva (once ... antimuscarinic side effects is potentially how, NVS might pitch NVA237 against Spiriva. We expect NVA237 to garner upto 25% of the LAMA market growing approximately ...
June 2011
2 pages
Eliquis (Apixaban) meets endpoints in ARISTOTLE - Stock Price Reaction premature
US$ 140.00
... from the ARISTOTLE trial, Eliquis met both, the primary (reduction in stroke and embolism) and secondary endpoint (reduction in major bleeding and ... stock price reaction is a bit premature, as detailed data is crucial to understand Eliquis relative efficacy/safety compared to Pradaxa and Xarelto. From a trial ...
June 2011
3 pages
REGENERON, Outperform - Is Trap Safer? Rilonacept vs. NVS’ Ilaris in Gout
US$ 90.00
... ) or colchicine primarily on safety concerns. Based on our analysis, we reiterate our Outperform rating on Regeneron (REGN) with a revised TP of $62 (vs. previous $65) as we believe both these drugs ... read our report released on 23rd June, 2011 on REGN named “Is Trap Safer? Rilonacept vs. NVS’ Ilaris in Gout”.
June 2011
5 pages
Israel Life Sciences Market Analysis
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,500.00 Hard Copy: US$ 900.00 CD-ROM: US$ 900.00 The field of life sciences has stipulated itself as one of the major businesses in Israel....
June 2011
55 pages
MSL-KOL Engagement: Ensuring Compliance
US$ 495.00
After its initial function to build rapport with KOLs, the MSL role has evolved from being a support to sales reps to the forefront of pharmaceutical practice. Lode Dewulf, chief medical affairs offic...
June 2011
47 pages
Global Wound Care Market Report: 2011 Edition
US$ 700.00
... reliability, price, and global reach, among such other factors. The report offers an analysis of the global wound care market. It also discusses key market trends, growth drivers ...
June 2011
34 pages
Competitor Analysis: Ras-Raf-MEK-ERK Inhibitors
US$ 660.00
... other pathywas such as the PI3K-Akt-mTOR pathways. Combining a mutant B-Raf inhibitor with a targeted T-cell antibody, such as ipilimumab, may increase ... ERK Pathway Corporate Ras-Raf-MEK-ERK Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers ...
June 2011
75 pages
Competitor Analysis: PI3K-AKT-mTOR Inhibitors
US$ 711.00
... effort has gone into developing agents that inhibit one or more PI3K isoforms, e.g. alpha and beta, as well as closely related proteins implicated in ... Others Corporate PI3K-AKT-mTOR Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, ...
June 2011
100 pages
Competitor Analysis: IGF-1R Antagonists
US$ 275.00
... -1/R antagonists Small Molecule Multi-target IGF-1/R antagonists Biologics as Selective IGF-1/R antagonists Biologics as Dual IGF-1/R antagonists Corporate IGF-1R Antagonist R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise ...
June 2011
26 pages
INTERCELL - No Tangible Value!
US$ 90.00
... on sideline, as there is no catalyst in 2011-12 that could boost the stock. Intercell (ICLL) woes of 2010 became worse in 2011 chiefly due to the ...
June 2011
1 pages
Catalysts Driven Investment Opportunities
US$ 140.00
... ) in the Biotech sector. The table lists the drug related catalysts for the Rising Star or Mature Biotech companies, our expectations ... of the series, which we will keep releasing in a timely manner. The catalysts include outcome of Advisory Committee Meetings (only June), PDUFA dates ...
June 2011
4 pages
Dr Reddy's PARA IV Pipeline Analysis
US$ 350.00
Dr Reddys has pipeline of ~20 Para IVs having branded sales of ~$24b. Among its Para IV pipeline the confirmed opportunities (branded sales ~$11.2b) are Exelon, Propecia, Zyprexa (20 mg), ... Nexium, Lipitor and Geodon. We expect PAT of ~$185m from the Dr. Reddy’s Para IVs which is ~3% of the current market Cap.
June 2011
21 pages
Lupin's PARA IV Pipeline Analysis
US$ 350.00
Lupin has pipeline of ~34 products having branded sales of ~$16b. Among its Para IV pipeline most lucrative opportunities are very few like that of Geodon, ... and Asacol. On other hand there are some Para IVs ...
June 2011
28 pages
Para IV presentation
US$ 350.00
A macro study on Indian Pharma Para IV litigations – a part of our recently introduced web based application - PARA IV Plus™ . This will provide you with a broad but meaningful insight to the prevalence of Indian Pharmaceutical companies in the Para IV space
June 2011
9 pages
RANBAXY'S PARA IV PIPELINE ANALYSIS
US$ 350.00
Ranbaxy has a pipeline of ~19 Para IV challenges, of which 12 are FTF’s. The total branded sales of these drugs under Para IV challenge by Ranbaxy is approximately $25b. Most of these Para ... offer decent upside. We expect Ranbaxy to generate a cumulative PAT of ~$950m from these Para IV opportunities, which is ...
June 2011
22 pages
Tarcva - EURTAC Data positive: Threat to Iressa in Firstline NSCLC
US$ 140.00
... by 63 % compared to chemotherapy (9.7 m vs 5.2 m). Interim analysis of EURTAC trial showed that Tarceva improved the overall survival by 4 m (22.9 m ... vs 18.8 m) compared to cisplatin chemotherapy. The data poses threat to AZN’s Iressa as it has not demonstrated OS ... lines of EGFR positive advanced NSCLC.
June 2011
2 pages
DISHMAN - Back To Basics
US$ 90.00
We reiterate our Underperform rating on Dishman despite it’s higher than expected Q4 FY11 result. The result was ...
May 2011
5 pages
Lupin Looses Combivir – A Big Blow To An Already Weak FY12 Pipeline
US$ 140.00
... for generic Combivir (Lamivudine + Zidovudine). With this approval, Teva has been granted and Lupin has ... ), Teva will launch its generic in Q4CY11. Lupin will be able to enter only after the 180 ... all other generics as well. We reiterate our Underperform on Lupin with target price of Rs.360 on the back of (1) ...
May 2011
2 pages
China Health Management Survey Report, 2011
US$ 1,400.00
With the development of Chinese economy, improvement of living standards and intensified aging population, Chinese people have growing demand for health management. In China, many industries are activ...
May 2011
62 pages
Market Access Europe: It's Not Just About Price
US$ 795.00
“May you live in interesting times.” Considered a curse by some, the saying could also be a blessing—especially when it comes to the evolving world of market access in Europe. Given its complex geo-po...
May 2011
71 pages
Healthcare IT Market in Emerging Economies (2010 - 2015)
US$ 3,390.00
... quality healthcare delivery by growing aging population, and increase in chronic disease patient population is driving the increased adoption of IT solutions in the emerging markets. The Healthcare IT markets in emerging economies is expected to grow from $5.3 billion in 2010 to $10.9 billion in 2015, at an estimated CAGR of 15.3% from 2010 to 2015. The hardware segment dominates the healthcare IT market in emerging ...
May 2011
259 pages
Global DNA & Gene Chip (Microarray) Market (2010 - 2015)
US$ 3,390.00
... the largest share – 98% – of the global DNA & gene chip market in 2010. Gene Expression currently forms the largest application market as gene expression products are used in a wide ... diagnostics, biodefense, and agriculture. While this application contributed 28% to the Global DNA & Gene Chip (microarray) market revenues in 2010, cancer diagnosis and treatment application ...
May 2011
331 pages
China Healthcare Sector Analysis
US$ 800.00
Single User PDF Format: US$ 800.00
Multi-User License: US$ 1,100.00
Hard Copy: US$ 900.00
CD-ROM: US$ 900.00 Chinese healthcare industry is entering into a new phase with the advanced...
April 2011
95 pages
South African Healthcare Market Analysis
US$ 1,000.00
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,600.00
Hard Copy: US$ 1,200.00
CD-ROM: US$ 1,200.00 South African Healthcare industry is one with a lot of scope, which i...
April 2011
75 pages
Human Albumin and Factor Vlll (FVIII) Markets: An Analysis
US$ 800.00
... conditions such as liver disease and hemorrhagic stroke. Another significant factor in albumin demand has been growing needs from emerging markets like ... profiles major players in the albumin and Factor VIII market. Further, we have predicted the future growth of albumin and Factor VIII market by combining SPSS ...
April 2011
45 pages
Hospital Market in China 2011
US$ 1,950.00
... report is sent in 0-2 business days after order is placed. The Hospital Market in China is growing steadily and has huge potential to grow in the near ... market overview section which gives an insight into the overall healthcare scenario in China along with the growth of hospitals and share of hospital ownership ...
April 2011
36 pages
Competitor Analysis: Adenosine Receptor Agonists & Antagonists
US$ 287.00
... and development of novel adenosine receptor agonists & antagonists. In addition, the report lists company-specific R&D pipelines of adenosine receptor agonists & antagonists in R&D. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, ...
April 2011
26 pages
Global Contract Manufacturing Market Analysis
US$ 1,500.00
Single User PDF Format: US$ 1,500.00
Multi-User License: US$ 2,200.00
Hard Copy: US$ 1,700.00
CD-ROM: US$ 1,700.00 The global pharmaceutical contract manufacturing industry has registe...
March 2011
70 pages
E-detailing Trends
US$ 495.00
Are we witnessing the death of the salesman?
Figures from a 2009 survey of physicians suggests that might be the case. Just 17 percent of doctors say they want traditional, linear contact fr...
March 2011
34 pages
Competitor Analysis RNA Therapeutics in Clinical Development
US$ 561.00
... online work with the project data to print or export an individual report. Although there are only two approved and marketed RNA based ... CpG Oligonucleotides Corporate Clinical Stage RNA Therapeutics R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but ...
March 2011
-
Competitor Analysis: Targeted Therapy of Obesity
US$ 706.00
... aminopeptidase 2 (MetAP2) Inhibitors f) Other Metabolic Modifiers 6) Various Approaches 7) Unspecified Targets Corporate Targeted Therapy of Obesity R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D ...
March 2011
80 pages
RNA Therapeutics Pipeline Database: 1-Year Subscription
US$ 847.00
... (RNAi) or Locked Nucleic Acid (LNA) RNA. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of ... illustrate the database. Purchase of the subscription provides a 1-year online access to the data of the RNA Therapeutics Pipeline Database. Credentials to access ...
March 2011
-
Building Strong Market Access Teams
US$ 395.00
A rock and a hard place. It’s not a comfortable spot to be, but increasingly, that’s where the pharmaceutical industry finds itself. Politicians in several European markets unilaterally cut prices for...
February 2011
36 pages
Competitor Analysis Interferon
US$ 619.00
Product description The Competitive Intelligence Report Interferon as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant and natural interferon alpha, beta, gamma, lambda and of other subtypes for treatment of hepatitis B and C, other ...
February 2011
89 pages
Therapeutic Protein Pipeline Database: 1-Year Subscription
US$ 1,613.00
... order, e.g. for phase, product category or company name. Sample screenshots illustrate the database. Purchase of the subscription provides a 1-year online access to the data of the Therapeutic Protein Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase ...
February 2011
-
Booming Hospital Services Market in India
US$ 800.00
Single User PDF Format: US$ 800.00
Multi-User License: US$ 1,200.00
Hard Copy: US$ 900.00
CD-ROM: US$ 900.00 The hospital services market represents one of the most lucrative segments...
January 2011
80 pages
